Amgen announced new data at the American Heart Association Scientific Sessions 2026 that further strengthen the case for more ...
Amgen (NASDAQ: AMGN) today announced new data at the American Heart Association (AHA) Scientific Sessions 2026 that further ...
If your doctor recently prescribed Repatha to help lower your "bad" LDL cholesterol and reduce the risk of heart disease, you may be wondering how it fits into the bigger picture of heart health.
Amgen announced results from a large real-world study showing that treatment with Repatha (evolocumab) reduced the risk of fatal or nonfatal heart attacks by 20% compared with ezetimibe in people with ...
--Amgen today announced new findings showing Repatha ® reduced the risk of death in high-risk adults without a prior heart attack or stroke when added to statins or other low-density lipoprotein ...
From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha-treated and placebo-treated patients, respectively. The most common ...
AbbVie’s Qulipta (atogepant tablets) has been approved for the preventive treatment of episodic migraine in adults. In the pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled, ...
WASHINGTON (Reuters) - The U.S. Food and Drug Administration on Thursday approved Amgen Inc's Repatha drug for patients with hereditary forms of high cholesterol and those with cardiovascular disease.
By Deena Beasley Nov 3 (Reuters) - Amgen on Tuesday said third-quarter sales rose 8%, led by demand for cholesterol drug ...
Amgen (NASDAQ: AMGN) today announced results from a large real-world study showing that treatment with Repatha ® (evolocumab) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results